10 Best Performing Pharma Stocks So Far in 2025

7. Corcept Therapeutics Incorporated (NASDAQ:CORT)

YTD Performance: 35.52%

Number of Hedge Fund Holders: 29

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company that develops and commercializes therapies that adjust the effects of cortisol, a hormone that regulates various bodily functions. The company’s flagship product, Korlym, is FDA-approved for treating Cushing’s syndrome, a disorder caused by excessive cortisol production.

In Q3 2024, the company reported revenue of $182.5 million, reflecting a 48% year-over-year increase. This growth was attributed to increased physician awareness of hypercortisolism and a growing number of patients receiving treatment with Korlym, the first medication approved by the FDA to serve patients with endogenous hypercortisolism. Its net income reached $47.2 million in the quarter, compared to $31.4 million in the same quarter last year. Management expects its revenue growth to continue, increasing its 2024 revenue guidance to $675 million to $700 million.

Corcept Therapeutics Incorporated’s (NASDAQ:CORT) next-generation drug candidate, relacorilant, is further supporting this growth momentum. Relacorilant is a selective cortisol regulator that has demonstrated promising results in two pivotal Phase 3 trials (GRACE and GRADIENT) for Cushing’s syndrome, and has potential to develop into a profitable drug. The company ranks seventh on our list of the 10 best-performing pharma stocks so far in 2025.

ClearBridge Small Cap Strategy stated the following regarding the company in its Q3 2024 investor letter:

“Another top contributor in health care, Corcept Therapeutics Incorporated (NASDAQ:CORT), saw its stock rise in the third quarter after strong earnings results and increased guidance for sales of Korlym, a hyperglycemia drug for adults with Cushing’s syndrome, which investors had been concerned would be vulnerable to the launch of a competitor’s generic version late last year. The company has seen added tailwinds from anticipation surrounding its next-generation version of the drug, which has fewer side effects, and is expected to release phase 3 data later this year and potentially file for FDA approval in 2025.”